Clinical Trials Sponsored by Sophini Logeswaran

Total 108 results

Sophini Logeswaran

Completed

Impact of ACT-based Interventions on Diabetes-related Outcomes

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1

United Kingdom
Sophiris Bio Corp

Completed

Randomized, Double-Blind, Vehicle-Controlled, Multicenter Safety and Efficacy Study of Intraprostatic PRX302 for LUTS BPH (PLUS-1)

Benign Prostatic Hyperplasia

United States, Australia, Canada, Russian Federation, Ukraine, New Zealand
Sophiris Bio Corp

Completed

Evaluate, Safety and Tolerability of Intraprostatic PRX302 Administration, Low to Intermediate Risk Prostate Cancer

Prostate Cancer

United Kingdom
Sophiris Bio Corp

Completed

Study of PRX302 for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia (BPH)

Benign Prostatic Hyperplasia

United States
Sophies Minde Ortopedi

Completed

Antiperspirant in the Treatment of Residual Limp Hyperhidrosis for Prosthetic Users

Hyperhidrosis | Residual Limbs

Norway
Sophiris Bio Corp

Completed

Intraprostatic PRX302 Injection to Treat Localised Prostate Cancer

Prostate Cancer

United Kingdom, United States
Sophiris Bio Corp

Completed

Transperineal Intraprostatic Injection of PRX302 Under Ultrasound Guidance for Management of Prostatic Hyperplasia (TRIUMPH-1)

Benign Prostatic Hyperplasia

Canada
Sophiris Bio Corp

Completed

PSA-Activated PSA-PAH1 for Locally Recurrent Prostate Cancer

Prostate Cancer

United States
Sophia Genetics SAS

Recruiting

Predictive Multimodal Signatures Associated With Response to Treatment and Prognosis of Patients With Stage IV Non-small Cell Lung Cancer (DEEP-Lung-IV)

Non-small Cell Lung Cancer Metastatic

United States, Spain, France, Israel, Germany, Canada, Italy, Brazil
Sophie Debrock

Completed

Morphometrics and Morphokinetics of Thawed Oocytes and Embryos

Infertility
Oslo University Hospital
Sophies Minde

Active, not recruiting

Unstable Distal Radius Fractures With Dorsal Dislocation in Patients Aged 18-64 Years. Volar Locking Plate (VLP) vs Closed Reduction and Percutaenous Pinning (CRPP).

Colles' Fracture | Distal Radius Fractures | Wrist Fracture

Norway
Sophiris Bio Corp

Withdrawn

Convection Enhanced Localized Administration of PRX321 With Real-time Imaging for Therapy of Recurrent Glioblastoma (CLARITY-1) (CLARITY-1)

Glioblastoma Multiforme
Sophiris Bio Corp

Completed

An Open-Label, Multi-Center, Phase IIa Trial of PRX302 Treatment of Patients With Locally Recurrent Prostate Cancer After Primary Radiation Therapy

Locally Recurrent Prostate Cancer

United States
Sophie Debrock

Completed

Day 3 Fresh Transfer Followed by Day 3 or Day 5 Vitrification of Supernumerary Embryos

Subfertility

Belgium
Sophie Debrock

Completed

The Effect of Vitrification Versus Slow Freezing on Day 3: a Randomised Controlled Trial.

Cryopreservation of Embryos

Belgium
Oslo University Hospital
Sophies Minde Foundation

Enrolling by invitation

Perthes Disease in Norway

Legg Calve Perthes Disease

Norway
Sophia Koutsogiannaki

Recruiting

Neutrophil Phenotypic Profiling and Acute Lung Injury in Patients After Cardiopulmonary Bypass (CPB)

Lung Injury | Cardiopulmonary Bypass

United States
Laboratorios Sophia S.A de C.V.

Completed

Phase IV Study to Evaluate the Efficacy of Lagricel® Ofteno PF Compared to Thealoz® Duo After Photorefractive Keratectomy (PRK) (PRO-037)

Photorefractive Keratectomy | Corneal De-epithelialization

Mexico
Laboratorios Sophia S.A de C.V.

Completed

Clinical Study to Evaluate the Safety of the Viscoelastic Substance PRO-149 When Used During Phacoemulsification, Compared to Healon® EndoCoat. (PRO-149)

Age-related Cataract | Phacoemulsification

Mexico
Laboratorios Sophia S.A de C.V.

Terminated

Efficacy of the Ophthalmic Pazufloxacin 0.6% for Bacterial Conjunctivitis, Compared to Gatifloxacin 0.3%. (PRO-157)

Conjunctivitis, Bacterial

Mexico
Laboratorios Sophia S.A de C.V.

Completed

Safety and Tolerability of the Ophthalmic Solution PRO-179 Compared With Travatan® (PRO-179/I)

Glaucoma

Mexico
Laboratorios Sophia S.A de C.V.

Completed

Efficacy and Safety of PRO-155 on Inflammation of the Conjunctival Surface in Subjects With Grade I-III Pterygium vs Placebo. (PRO-155/IV)

Ocular Inflammation | Ocular Pain | Pterygium | Post-surgical Inflammation

Mexico
Laboratorios Sophia S.A de C.V.

Terminated

Non-inferiority of PRO-067 Ophthalmic Solution vs GAAP Ofteno® in Glaucoma or Ocular Hypertension (COMPLIANCE)

Primary Open Angle Glaucoma | Ocular Hypertension

Mexico
Laboratorios Sophia S.A de C.V.

Completed

Safety and Tolerability of PRO-155 Ophthalmic Solution 0.09% in Healthy Volunteers. (PRO-155)

Inflammation | Cataract

Mexico
Laboratorios Sophia S.A de C.V.

Completed

Safety and Efficacy of PRO-157 vs Moxifloxacin vs Gatifloxacin in Patients With Bacterial Conjunctivitis (Pazufloxacin) (Pazufloxacin)

Bacterial Conjunctivitis

Mexico
Laboratorios Sophia S.A de C.V.

Completed

Efficacy and Safety of PRO-155 Versus Nevanac in Post Phacoemulsification

Cataract | Phacoemulsification Cataract Surgery

Mexico
Laboratorios Sophia S.A de C.V.

Withdrawn

Clinical Efficacy of PRO-118 Compared With Olopatadine Hydrochloride Ophthalmic Solution in Allergic Conjunctivitis

Allergic Conjunctivitis
Laboratorios Sophia S.A de C.V.

Completed

Efficacy and Safety of PRO-148 Versus Systane®, in Patients With Mild to Moderate Dry Eye

Dry Eye

Mexico
Laboratorios Sophia S.A de C.V.

Not yet recruiting

Clinical Study to Evaluate the Safety and Tolerability of PRO-229 Ophthalmic Solution Compared to Lagricel® Ofteno PF

Ocular Surface Disease | Dry Eye Disease
Laboratorios Sophia S.A de C.V.

Not yet recruiting

Study Evaluating PRO-232 an Ophthalmic Solution Compared to Placebo. (PRO-232)

Healthy
Laboratorios Sophia S.A de C.V.

Recruiting

Clinical Study to Evaluate PRO-169 for Diabetic Macular Edema (PRO-169)

Diabetic Macular Edema

Colombia, Mexico
Laboratorios Sophia S.A de C.V.

Completed

Phase IV Clinical Study to Compare the Efficacy of the Ophthalmic Solution Humylub Ofteno® PF With Hyabak® and Lagricel Ofteno® PF as Treatment for Dry Eye. (PRO-087)

Dry Eye

Mexico
Laboratorios Sophia S.A de C.V.

Withdrawn

Safety and Tolerability Evaluation of PRO-230 Ophthalmic Solution (PRO-230)

Myopia
Laboratorios Sophia S.A de C.V.

Terminated

Comparative Study of the Efficacy of Either Krytantek Ofteno PF® or Eliptic Ofteno PF® Plus Gaap Ofteno PF® for POAG or Ocular Hypertension. (PRO-122)

Ocular Hypertension | Glaucoma, Open-Angle

Mexico
Laboratorios Sophia S.A de C.V.

Completed

Safety and Tolerability of the Preservative-free Ophthalmic Solution PRO-122 Compared With Krytantek Ofteno® (PRO-122/I)

Glaucoma

Mexico
Laboratorios Sophia S.A de C.V.

Completed

Non-inferiority of PRO-122 Ophthalmic Solution vs KRYTANTEK Ofteno® in Glaucoma or Ocular Hypertension (CONFORTK) (CONFORTK)

Primary Open Angle Glaucoma | Ocular Hypertension
Laboratorios Sophia S.A de C.V.

Completed

Clinical Study of A Fixed Combination of Timolol-Brimonidine-Dorzolamide

Primary Open Angle Glaucoma | Ocular Hypertension

Mexico
Laboratorios Sophia S.A de C.V.

Completed

Safety and Tolerability of PRO-087 Versus Xyel Ofteno® and Systane Ultra®, on the Ocular Surface of Healthy Subjects (PRO-087/I)

Dry Eye Syndromes | Lubricant Allergy | Tear Disorder

Mexico
Laboratorios Sophia S.A de C.V.

Completed

Efficacy and Safety of PRO-148 Ophthalmic Solution Versus SYSTANE® in the Treatment of Patients With Dry Eye Syndrome (PRO-148)

Dry Eye Syndrome

Mexico
Laboratorios Sophia S.A de C.V.

Withdrawn

Safety and Tolerability of PRO-143 Ophthalmic Solution in Healthy Volunteers. (PRO-143)

Conjunctivitis, Bacterial

Mexico
Oslo University Hospital
Sophies Minde AS

Completed

Femoral Lengthening Might Impair Physical Function and Lead to Structural Changes in Adjacent Joints

Quality of Life | Osteoarthritis, Knee | Leg Length Inequality | Osteoarthritis of Hip | Leg; Lengthening

Norway
Laboratorios Sophia S.A de C.V.

Not yet recruiting

Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface.

Dry Eye | Dry Eye Syndromes | Dry Eyes Chronic
Laboratorios Sophia S.A de C.V.

Not yet recruiting

Study to Evaluating PRO-240 Ophthalmic Solution Compared to Optive®

Ocular Surface Disease | Dry Eye Disease | Dry Eye Sensation
Laboratorios Sophia S.A de C.V.

Not yet recruiting

Study of Non-inferiority Between Manzanilla Sophia® and Meticel Ofteno® 0.5% for Providing a Soothing Sensation to the Eyes.

Eye Strain | Eye Strain of Both Eyes
Laboratorios Sophia S.A de C.V.

Recruiting

Study to Evaluate the Safety and Tolerability of PRO-231 Ophthalmic Solution Versus VIGAMOXI® on the Ocular Surface of Healthy Subjects.

Bacterial Conjunctivitis | Ophthalmological Agent Toxicity

Mexico
Al-Azhar University
Sphinx university

Not yet recruiting

The Efficacy of Selenium as an Alternative or Complementary Topical Treatment of Oral Lichen Planus (RCT)

Lichen Planus, Oral

Egypt
Laboratorios Sophia S.A de C.V.

Recruiting

PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM) (PRO-122LATAM)

Primary Open-angle Glaucoma

Colombia, Mexico
Laboratorios Sophia S.A de C.V.

Active, not recruiting

Safety and Tolerability of the Ophthalmic Gel PRO-165 Versus Artelac® Nightime Gel (PRO-165)

Dry Eye Syndromes

Mexico
Laboratorios Sophia S.A de C.V.

Completed

Safety and Tolerability of PRO-185 (PRO-185)

Hyperemia Eye

Mexico
Laboratorios Sophia S.A de C.V.

Completed

Phase I Clinical Trial to Evaluate the Safety and Tolerability of Ophtalmic Solution PRO-201 (PRO-201)

Myopia

Mexico

3

Subscribe